Picard Medical Faces Securities Class Action Over Alleged Stock-Promotion Scheme

Overview

• Investor-rights law firms announced a filed case targeting Picard Medical and invited shareholders to pursue lead-plaintiff status under contingency fee arrangements.
• The complaint covers Sept. 2 to Oct. 31, 2025, and claims a social-media push used false claims and impersonated financial advisors to hype the stock.
• Plaintiffs allege insiders or affiliates moved shares through offshore or nominee accounts to coordinate buying and then dump stock during a price run-up.
• The suit says Picard left these promotion and trading efforts out of its risk disclosures, which made positive statements about its outlook misleading.
• Next steps focus on selecting a lead plaintiff in early to mid April 2026, and no class has been certified or claims proven at this stage.